Prostate Cancer | Pharmacor | G7 | 2014
Last Updated 24 October 2014
The prostate cancer market has witnessed considerable changes over the last four years with the launch of five therapies for metastatic castrate-resistant prostate cancer (mCRPC). Abiraterone (Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s Zytiga) is established as a key agent to treat mCRPC; enzalutamide follows abiraterone and promises to compete fiercely for a share of this market, including in the commercially lucrative first-line chemotherapy-naive mCRPC setting. A number of emerging therapies are in Phase III development for prostate cancer, including for the untapped nonmetastatic CRPC (nmCRPC) patient population. The expected launch of several emerging therapies for prostate cancer over the next decade will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.
